Biotech

All Articles

Analysts explore Avidity's DMD win, showing distinctions in information

.Avidity Biosciences satisfied entrepreneurs along with period 1/2 data in Duchenne muscular dystrop...

Actinogen's cortisol blocker falls short phase 2 anxiety research study

.Actinogen Medical's cortisol blocker has actually missed the primary endpoint of a stage 2 study in...

Bivictrix chooses going private only way to take ADC into center

.Antibody-drug conjugates (ADCs) have actually gone to the facility of many a billion-dollar biobuck...

TPG leadings up funds to $580M for expenditures around lifestyle scientific researches

.Property supervisor TPG, which has assisted biotechs such as Sionna Therapies and Santa Ana Biograp...

Merck ceases period 3 TIGIT trial in bronchi cancer cells for impossibility

.Merck &amp Co.'s TIGIT course has suffered an additional trouble. Months after shuttering a phase 3...

After a difficult year, Exscientia folds into Recursion

.After a year determined through pipe hairstyles, the shift of its chief executive officer as well a...

Cullinan, after $25M offer, hands back bispecific to Port

.Cullinan Therapy was thrilled good enough with Harbour BioMed's bispecific invulnerable activator t...

A nearer consider Fierce Biotech's Intense 15

.In this week's incident of "The Best Line," our team're diving right into Fierce Biotech's yearly F...

Lilly encounters period 2 failing of tau-targeting med

.The confetti is still flying from Eli Lilly's gathering celebrating the approval of Alzheimer's ill...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Accept to recently's Chutes &amp Ladders, our roundup of significant management hirings, firings as...